These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 24507530)

  • 41. Bayesian design of single-arm phase II clinical trials with continuous monitoring.
    Johnson VE; Cook JD
    Clin Trials; 2009 Jun; 6(3):217-26. PubMed ID: 19528131
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Optimal design and analysis of phase I/II clinical trials in multiple sclerosis with gadolinium-enhanced lesions as the endpoint.
    Healy BC; Ikle D; Macklin EA; Cutter G
    Mult Scler; 2010 Jul; 16(7):840-7. PubMed ID: 20530124
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Using Bayesian modeling in frequentist adaptive enrichment designs.
    Simon N; Simon R
    Biostatistics; 2018 Jan; 19(1):27-41. PubMed ID: 28520893
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A placebo arm is not always necessary in clinical trials of amyotrophic lateral sclerosis.
    Gordon PH
    Muscle Nerve; 2009 Jun; 39(6):858-60. PubMed ID: 19382169
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Low-dose (7.5 mg) oral methotrexate for chronic progressive multiple sclerosis. Design of a randomized, placebo-controlled trial with sample size benefits from a composite outcome variable including preliminary data on toxicity.
    Goodkin DE; Rudick RA; VanderBrug Medendorp S; Greene T; Schwetz KM; Fischer J; Daughtry MM; Ross J; Van Dyke C
    Online J Curr Clin Trials; 1992 Sep; Doc No 19():[7723 words; 89 paragraphs]. PubMed ID: 1343611
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Revisiting the multiple sclerosis functional composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures.
    Ontaneda D; LaRocca N; Coetzee T; Rudick R;
    Mult Scler; 2012 Aug; 18(8):1074-80. PubMed ID: 22740488
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Regulatory perspectives on multiplicity in adaptive design clinical trials throughout a drug development program.
    Wang SJ; Hung HM; O'Neill R
    J Biopharm Stat; 2011 Jul; 21(4):846-59. PubMed ID: 21516573
    [TBL] [Abstract][Full Text] [Related]  

  • 48. ECNP consensus meeting. Bipolar depression. Nice, March 2007.
    Goodwin GM; Anderson I; Arango C; Bowden CL; Henry C; Mitchell PB; Nolen WA; Vieta E; Wittchen HU
    Eur Neuropsychopharmacol; 2008 Jul; 18(7):535-49. PubMed ID: 18501566
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Adaptive designs for clinical trial].
    Li W; He SJ; Wang Y; Cheng XR; Jia X
    Zhonghua Liu Xing Bing Xue Za Zhi; 2007 Jun; 28(6):605-7. PubMed ID: 17939395
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficiencies of platform clinical trials: A vision of the future.
    Saville BR; Berry SM
    Clin Trials; 2016 Jun; 13(3):358-66. PubMed ID: 26908536
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Shuffling Adaptive Clinical Trials.
    Gokhale SG; Gokhale S
    Am J Ther; 2016; 23(3):e663-9. PubMed ID: 23751329
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MRI measures should be a primary outcome endpoint in Phase III randomized, controlled trials in multiple sclerosis: yes.
    Sormani MP; De Stefano N
    Mult Scler; 2014 Mar; 20(3):280-1. PubMed ID: 24589685
    [No Abstract]   [Full Text] [Related]  

  • 53. The design of clinical studies to assess therapeutic efficacy in multiple sclerosis.
    Brown JR; Beebe GW; Kurtzke JF; Loewenson RB; Silberberg DH; Tourtellotte WW
    Neurology; 1979 Sep; 29(9 pt. 2):3-23. PubMed ID: 381971
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Why non-inferiority is more challenging than superiority?
    Sormani MP
    Mult Scler; 2017 May; 23(6):790-791. PubMed ID: 28350235
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Model-Based Assessment of Alternative Study Designs in Pediatric Trials. Part I: Frequentist Approaches.
    Smania G; Baiardi P; Ceci A; Magni P; Cella M
    CPT Pharmacometrics Syst Pharmacol; 2016 Jun; 5(6):305-12. PubMed ID: 27300083
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A referendum on clinical trial research in multiple sclerosis: the opinion of the participants at the Jekyll Island workshop.
    Noseworthy JH; Vandervoort MK; Hopkins M; Ebers GC
    Neurology; 1989 Jul; 39(7):977-81. PubMed ID: 2739925
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Assessing social validity in clinical treatment research: issues and procedures.
    Foster SL; Mash EJ
    J Consult Clin Psychol; 1999 Jun; 67(3):308-19. PubMed ID: 10369051
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Optimized adaptive enrichment designs.
    Ondra T; Jobjörnsson S; Beckman RA; Burman CF; König F; Stallard N; Posch M
    Stat Methods Med Res; 2019 Jul; 28(7):2096-2111. PubMed ID: 29254436
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A novel evaluation of optimality for randomized controlled trials.
    Wick J; Berry SM; Yeh HW; Choi W; Pacheco CM; Daley C; Gajewski BJ
    J Biopharm Stat; 2017; 27(4):659-672. PubMed ID: 27295566
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Innovative Designs, Methods and Application for Disease Risk Prediction and Drug Development: Frequentist, Bayesian, and Beyond.
    Contemp Clin Trials; 2017 Dec; 63():1. PubMed ID: 29153293
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.